Abstract
Background: Apolipoprotein E (ApoE) is the major genetic risk factor for sporadic Alzheimer's Disease (AD). Some studies showed a relationship between ApoE4 genotype and the cerebrospinal fluid (CSF) biomarkers (β-amyloid42, p-Tau, t-Tau), as well as with cognitive status. In this sense, it could be interesting to develop an approach to establish amyloid status in a minimally invasive way.
Methods: The present study assessed the ApoE genotype in different participant groups (mild cognitive impairment due to AD (MCI-AD), mild/moderate dementia due to AD, MCI not due to AD (MCI not AD), other neurological diseases, healthy participants) (n = 342).
Results: As expected, the ApoE4 allele was more prevalent in AD patients, characterized by impairment in CSF β-amyloid42 levels (Aβ +), than in the other groups (Aβ -). In this sense, ApoE4-carrier subjects showed lower CSF levels for β-amyloid42 and higher CSF levels for t-Tau and p-Tau. From this, a multivariate model to predict Aβ status was developed by means of partial least square analysis (PLS) and predictive variables (ApoE genotype, cognitive score, sex, age). This model showed suitable AUC-ROC 0.792 (95% CI, 0.744-0.840) and predictive negative value (81.6%).
Conclusion: ApoE genotype could be useful in detecting CSF β-amyloid42 impairment associated with early AD development.
Keywords: Alzheimer Disease, apolipoprotein E, diagnosis, amyloid, screening, β-amyloid.
Current Alzheimer Research
Title:Assessment of apolipoprotein E genotype for β-amyloid status prediction
Volume: 18 Issue: 13
Author(s): Carmen Peña-Bautista, Lourdes Álvarez-Sánchez, Lorena García, Miguel Baquero and Consuelo Cháfer-Pericás*
Affiliation:
- Alzheimer's Disease Research Group, Health Research Institute La Fe, Valencia,Spain
Keywords: Alzheimer Disease, apolipoprotein E, diagnosis, amyloid, screening, β-amyloid.
Abstract: Background: Apolipoprotein E (ApoE) is the major genetic risk factor for sporadic Alzheimer's Disease (AD). Some studies showed a relationship between ApoE4 genotype and the cerebrospinal fluid (CSF) biomarkers (β-amyloid42, p-Tau, t-Tau), as well as with cognitive status. In this sense, it could be interesting to develop an approach to establish amyloid status in a minimally invasive way.
Methods: The present study assessed the ApoE genotype in different participant groups (mild cognitive impairment due to AD (MCI-AD), mild/moderate dementia due to AD, MCI not due to AD (MCI not AD), other neurological diseases, healthy participants) (n = 342).
Results: As expected, the ApoE4 allele was more prevalent in AD patients, characterized by impairment in CSF β-amyloid42 levels (Aβ +), than in the other groups (Aβ -). In this sense, ApoE4-carrier subjects showed lower CSF levels for β-amyloid42 and higher CSF levels for t-Tau and p-Tau. From this, a multivariate model to predict Aβ status was developed by means of partial least square analysis (PLS) and predictive variables (ApoE genotype, cognitive score, sex, age). This model showed suitable AUC-ROC 0.792 (95% CI, 0.744-0.840) and predictive negative value (81.6%).
Conclusion: ApoE genotype could be useful in detecting CSF β-amyloid42 impairment associated with early AD development.
Export Options
About this article
Cite this article as:
Peña-Bautista Carmen, Álvarez-Sánchez Lourdes, García Lorena, Baquero Miguel and Cháfer-Pericás Consuelo *, Assessment of apolipoprotein E genotype for β-amyloid status prediction, Current Alzheimer Research 2021; 18 (13) . https://dx.doi.org/10.2174/1567205019666211223141524
DOI https://dx.doi.org/10.2174/1567205019666211223141524 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements